Filing Flows › Comparisons › STRO vs RGNX
Sutro Biopharma vs Regenxbio: STRO and RGNX compared
Sutro Biopharma is the larger company: $9.8M of revenue in its latest quarter (Q2 2026) against $9.2M for Regenxbio (Q3 2026). Regenxbio is growing faster (-69% against -85% a year earlier). Sutro Biopharma is more profitable, with an operating margin of -303.8% against -387.8%.
Where the money goes: STRO and RGNX
Sutro Biopharma (STRO) · Q2 2026
Sutro Biopharma, Q2 2026: revenue $9.8M (-85% year over year), operating margin -303.8%, net loss $38.5M, operating cash flow −$38.3M. The chart follows the revenue to costs, profit and cash.
Regenxbio (RGNX) · Q3 2026
Regenxbio, Q3 2026: revenue $9.2M (-69% year over year), operating margin -387.8%, net loss $40.7M, operating cash flow $38.6M. The chart follows the revenue to costs, profit and cash.
| Sutro Biopharma (STRO) | Regenxbio (RGNX) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $9.8M | $9.2M |
| Revenue growth, Y/Y | -85% | -69% |
| Operating margin | -303.8% | -387.8% |
| Net earnings | −$38.5M | −$40.7M |
| Net margin | -391.6% | -444.6% |
| Operating cash flow | −$38.3M | $38.6M |
| Free cash flow | — | $38.4M |
Where the revenue comes from
Regenxbio
- License and Service: $5.2M (57%)
- Service: $3.9M (43%)
Questions
Which is bigger, Sutro Biopharma or Regenxbio?
Sutro Biopharma is the larger company: $9.8M of revenue in its latest quarter (Q2 2026) against $9.2M for Regenxbio (Q3 2026).
Is Sutro Biopharma or Regenxbio growing faster?
Regenxbio is growing faster (-69% against -85% a year earlier).
Which is more profitable, Sutro Biopharma or Regenxbio?
Sutro Biopharma is more profitable, with an operating margin of -303.8% against -387.8%.
More: Sutro Biopharma earnings · how Sutro Biopharma makes money · Regenxbio earnings · how Regenxbio makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.